Results 51 to 60 of about 10,701 (213)

Unraveling Suicidal Ideation and Behaviors in a Global Cohort of Individuals at Clinical High‐Risk for Psychosis: Multivariable Correlates and Subthreshold Psychotic Symptoms

Acta Psychiatrica Scandinavica, EarlyView.
ABSTRACT Introduction Suicidal ideation and behaviors (SIB) are common among individuals at clinical high risk for psychosis (CHR‐P), but their relationship with the overall clinical profile remains unclear. This study aimed to identify sociodemographic/clinical factors associated with SIB in CHR‐P individuals and to examine whether subthreshold ...
Stefano Damiani, Marika Orlandi, Umberto Provenzani, Elisa Bortolin, Margherita Rovida, Riccardo Stefanelli, Jean Addington, Luis Alameda, Celso Arango, Nicholas J. K. Breitborde, Matthew R. Broome, Kristin S. Cadenhead, Monica E. Calkins, Ricardo E. Carrion, Rolando I. Castillo‐Passi, Eric Yu Hai Chen, Jimmy Choi, Philippe Conus, Barbara A. Cornblatt, Covadonga M. Diaz‐Caneja, Lauren M. Ellman, Abigayle Fogarty, Pablo A. Gaspar, Carla Gerber, Louise Birkedal Glenthøj, Leslie E. Horton, Christy Lai Ming Hui, Joseph Kambeitz, Lana Kambeitz‐Ilankovic, Matcheri S. Keshavan, Minah Kim, Sung‐Wan Kim, Nikolaos Koutsouleris, Zsuliet Kristof, Jun Soo Kwon, Kerstin Langbein, Daniel Mamah, Daniel H. Mathalon, Vijay A. Mittal, Josh Nguyen, Merete Nordentoft, Godfrey D. Pearlson, Nora Penzel, Jesus Perez, Diana O. Perkins, Albert R. Powers III, Jack Rogers, Fred W. Sabb, Jason Schiffman, Jai L. Shah, Steven M. Silverstein, Stefan Smesny, William S. Stone, Gregory P. Strauss, Judy L. Thompson, Rachel Upthegrove, Swapna Verma, Cassandra Wannan, Jijun Wang, Heather Wastler, Daniel H. Wolf, Tianhong Zhang, Sylvain Bouix, Cheryl M. Corcoran, Tina Kapur, Ofer Pasternak, Carrie E. Bearden, Rene S. Kahn, John M. Kane, Patrick D. McGorry, Barnaby Nelson, Martha E. Shenton, Scott W. Woods, Paolo Fusar‐Poli   +73 more
wiley   +1 more source

DECRIMINALIZES PSILOCYBIN MUSHROOMS. INITIATIVE STATUTE. [PDF]

, 2019
Decriminalizes under state law the personal possession, storage, use, cultivation, manufacturing, giving away or furnishing for personal use, or consumption of psilocybin mushrooms and the hallucinogenic chemical compounds contained in them (including ...

core   +5 more sources

Therapeutic use of psilocybin: Practical considerations for dosing and administration

Frontiers in Psychiatry, 2022
The interest in psilocybin as a therapeutic approach has grown exponentially in recent years. Despite increasing access, there remains a lack of practical guidance on the topic for health care professionals.
Caroline A. MacCallum, Lindsay A. Lo, Carly A. Pistawka, Jagpaul Kaur Deol   +3 more
doaj   +1 more source

Psychedelic‐assisted treatment for substance use disorder: A narrative systematic review

Addiction, EarlyView.
Abstract Background and aims This is the first systematic review of the extant literature on all major psychedelic‐assisted treatment for alcohol use disorder (AUD), tobacco use disorder (TUD) and other substance use disorders (SUD). We aimed to summarise the evidence for efficacy of psychedelic‐assisted treatment for AUD, TUD, and SUD; to evaluate its
Theodore Piper, Francesca Small, Sam Brown, Michael Kelleher, Luke Mitcheson, James Rucker, Allan H. Young, John Marsden   +7 more
wiley   +1 more source

How to become a licensed psilocybin manufacturer in Oregon. Spanish

, 2023
Title from PDF caption (viewed on February 16, 2023).This archived document is maintained by the State Library of Oregon as part of the Oregon Documents Depository Program.

core  

265 Self-reported rates of psilocybin use in North Florida, 2012 to present

Journal of Clinical and Translational Science
Objectives/Goals: Mainstream interest in psilocybin (“shrooms”) has grown over the past several years as two US states have “legalized” psilocybin and clinical trials are underway for use in multiple mental health conditions.
Tamara Millay, Monica Bhargavi Kodali, Linda Cottler   +2 more
doaj   +1 more source

Acute and long-term effects of psilocybin on energy balance and feeding behavior in mice

Translational Psychiatry, 2022
Psilocybin and other serotonergic psychedelics have re-emerged as therapeutics for neuropsychiatric disorders, including addiction. Psilocybin induces long-lasting effects on behavior, likely due to its profound ability to alter consciousness and augment
Nicole Fadahunsi, Jens Lund, Alberte Wollesen Breum, Cecilie Vad Mathiesen, Isabella Beck Larsen, Gitte Moos Knudsen, Anders Bue Klein, Christoffer Clemmensen   +7 more
doaj   +1 more source

Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial

Addiction, EarlyView.
Abstract Background and Aims Psilocybin has emerged as a potential treatment for alcohol use disorder (AUD), but early efficacy data are inconsistent. Depression following alcohol detoxification significantly increases the risk of relapse. This pilot study aimed to evaluate the feasibility, acceptability, and preliminary efficacy of psilocybin‐assisted
Amandine Luquiens, Dahbia Belahda, Carine Graux, Noe Igounenc, Chris Serrand, Paul Rochefort, Thibault Mura, Felix Sergent   +7 more
wiley   +1 more source

Psilocybin: Magic Mushrooms

, 2023
<p>Psilocybin, a naturally occurring psychedelic compound found in certain species of mushrooms, has been intriguing scientists and researchers with its potential therapeutic properties.
Render PhD, Dr. David
core   +1 more source

Decriminalization of Psilocybin. Initiative Statute. [PDF]

, 2017
Decriminalizes use, possession, sale, transport, or cultivation of psilocybin (a hallucinogenic compound) by persons at least 21 years of age. Summary of estimate by Legislative Analyst and Director of Finance of fiscal impact on state and local ...

core   +4 more sources